Fig. 4: Therapeutic efficacy of vMOs in cell experiments. | npj Digital Medicine

Fig. 4: Therapeutic efficacy of vMOs in cell experiments.

From: Machine learning-driven glycolytic subtyping and exosome-based PKM splicing modulation overcome drug resistance in hyper-glycolytic myeloid leukemia

Fig. 4

A–E Expression levels of the PKM1 and PKM2 proteins (A), the cell cycle (B, C), apoptosis rates (D, E), and cell activity (K) were evaluated in K562 cells following transfection with IM (0.2 μmol/l), vMO (10 μmol/l), or a combination of both drugs. F–J Expression levels of the PKM1 and PKM2 proteins (F), the cell cycle (G, H), apoptosis rates (I, J), and cell activity (L) were assessed in K562/G01 cells after transfection with IM (2 μmol/l), vMO (10 μmol/l), or a combination of both drugs.

Back to article page